Veterinary diagnostics maker IDEXX reported on Thursday that its revenues for the second quarter grew 6% year over year to $413 million, as placements of its blood analysis systems hit a record of 900 units for the period. Placements of its Catalyst One next-generation chemistry analyzer skyrocketed 44% to an all-time record of 1,100 units, the company said in a press release announcing the results.
Distributor Henry Schein, which is undergoing a major expansion of its animal health business, reported that earnings in the second quarter grew 8% year over year to $123.2 million or $1.46 per diluted share, on sales that rose a half-percent to $2.6 billion.
Zimmer Biomet officials spent the newly combined company's Q2 2015 earnings call describing the company's sales and marketing strategy as it seeks to ramp up growth in 2016 following ongoing integration efforts. The company reiterated its pledge to retain sales reps rather than cut them in an effort to achieve synergies.
Moving quickly to show investors a change of direction is ahead, Novogen acting Chief Executive Iain Ross announced a company-wide review of its preclinical programs less than a week after the abrupt departure of his predecessor, Graham Kelly.
AstraZeneca's closely watched blood thinner Brilinta came through for the drugmaker in the second quarter, as did its diabetes franchise, allowing the British company to pull off a 2% rise in sales (at constant exchange rates) to $6.3 billion and core operating profit of $1.8 billion, or $1.21 a share.
Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.
PRA Health Sciences is ticking up its full-year expectations after another quarter of revenue growth, counting on a steady stream of new business.
Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.
India's Biocon easily reached the top end of its offer range for an initial public offering of shares in CRO Syngene, a source said, adding that recent reports of troubles at other Indian companies in the sector had no impact on demand.
Veterinary diagnostics maker Heska's stock has more than doubled since last year, but it's clearly experiencing some growing pains. On Wednesday, Heska missed analysts' sales targets for the second quarter, reporting year-over-year revenue growth of 4% to 23.9 million. Analysts had been expecting revenues of $24.3 million.